Exelixis, Inc. ã¯ãè
«çåŠã«éç¹ã眮ãããã€ãªãã¯ãããžãŒäŒæ¥ã§ãããç±³åœã§çãæ²»çããããã®æ°è¬ã®çºèŠãéçºãããã³åååã«æ³šåããŠããŸããå瀟ã®è£œåã«ã¯ã以åã«æè¡ç®¡æ°ççæ³ãåããé²è¡æ§è
现èçã®æ£è
ã®æ²»ççšã® CABOMETYX é å€ãé²è¡æ§ããã³è»¢ç§»æ§ç²ç¶è
ºé«æ§çã®æ£è
ã®æ²»ççšã® COMETRIQ ã«ãã»ã«ãªã©ããããŸããCABOMETYX ãš COMETRIQ ã¯ãMETãAXLãRETãVEGF å容äœãå«ãè€æ°ã®ããã·ã³ãããŒãŒã®é»å®³å€ã§ããã«ãã¶ã³ãããããæŽŸçãããã®ã§ããå瀟ã¯ãŸããé²è¡æ§é»è²è
«ã®æ²»çã®ããã®äœµçšçæ³ãšã㊠MEK é»å®³å€ COTELLIC ããæ¥æ¬ã§é«è¡å§ã®æ²»çã®ããã®çµå£éã¹ããã€ãæ§éžæçããã©ã«ã³ã«ãã³ã€ãå容äœé®æè¬ MINNEBRO ãæäŸããŠããŸããããã«ãExelixis, Inc. ã¯ãVEGF å容äœãMETãAXLãMERãããã³çã®å¢æ®ã𿡿£ã«é¢äžãããã®ä»ã®ãããŒãŒãæšçãšããçµå£ããã·ã³ãããŒãŒé»å®³å€ XL092 ãéçºäžã§ããExelixis, Inc. ã¯ãIpsen Pharma SASãæŠç°è¬åå·¥æ¥æ ªåŒäŒç€ŸãF. Hoffmann-La Roche Ltd.ãRedwood Bioscience, Inc.ãRP Scherer Technologies, LLCãCatalent Pharma Solutions, Inc.ãNBE Therapeutics AGãAurigene Discovery Technologies LimitedãIconic Therapeutics, Inc.ãInvenra, Inc.ãStemSynergy Therapeutics, Inc.ãGenentech, Inc.ãGlaxoSmithKlineãBristol-Myers Squibb Companyãããã³ç¬¬äžäžå
±æ ªåŒäŒç€Ÿãšå
±åç ç©¶ããã³ã©ã€ã»ã³ã¹å¥çŽãçµãã§ããŸããå瀟ã¯ä»¥åã¯Exelixis Pharmaceuticals, Inc.ãšããŠç¥ãããŠããŸãããã2000幎2æã«Exelixis, Inc.ã«ç€Ÿåã倿ŽããŸãããExelixis, Inc.ã¯1994幎ã«èšç«ãããã«ãªãã©ã«ãã¢å·ã¢ã©ã¡ãã«æ¬ç€Ÿã眮ããŠããŸãã